Author:
Sviggum Hans P.,Sprung Juraj
Reference8 articles.
1. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997;25(9):1072–80.
2. McClain DA, Hug Jr CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980;28(1):106–14.
3. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir’s role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology. 1999;91(3):681–5.
4. Kharasch ED, Whittington D, Hoffer C. Minimal influence of hepatic & intestinal CYP3A activity on the acute disposition & effect of oral transmucosal fentanyl (OTFC) [abstract]. Anesthesiology. 2003;99:A515.
5. Rowland M, Tozer TN. Elimination. In: Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams & Wilkins; 1995. p. 156–83.